Proteon Therapeutics (PRTO) Rating Increased to Outperform at JMP Securities

Share on StockTwits

JMP Securities upgraded shares of Proteon Therapeutics (NASDAQ:PRTO) from a market perform rating to an outperform rating in a report issued on Monday morning, MarketBeat Ratings reports.

PRTO has been the topic of a number of other research reports. Zacks Investment Research cut Proteon Therapeutics from a hold rating to a sell rating in a research report on Friday, January 18th. HC Wainwright set a $3.00 price target on Proteon Therapeutics and gave the company a buy rating in a research report on Friday, January 25th. Finally, Maxim Group started coverage on Proteon Therapeutics in a research report on Tuesday, October 30th. They set a buy rating and a $5.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Proteon Therapeutics currently has an average rating of Buy and a consensus target price of $3.50.

Shares of NASDAQ PRTO opened at $2.99 on Monday. Proteon Therapeutics has a one year low of $1.50 and a one year high of $3.10. The firm has a market cap of $56.13 million, a PE ratio of -1.40 and a beta of 0.77.

Several large investors have recently added to or reduced their stakes in PRTO. New Leaf Venture Partners L.L.C. increased its stake in Proteon Therapeutics by 1.5% in the 4th quarter. New Leaf Venture Partners L.L.C. now owns 1,523,200 shares of the biopharmaceutical company’s stock worth $3,458,000 after acquiring an additional 23,200 shares during the last quarter. Comprehensive Portfolio Management LLC bought a new position in Proteon Therapeutics in the 4th quarter worth about $68,000. Vanguard Group Inc increased its stake in Proteon Therapeutics by 45.9% in the 3rd quarter. Vanguard Group Inc now owns 209,383 shares of the biopharmaceutical company’s stock worth $408,000 after acquiring an additional 65,833 shares during the last quarter. Vanguard Group Inc. increased its stake in Proteon Therapeutics by 45.9% in the 3rd quarter. Vanguard Group Inc. now owns 209,383 shares of the biopharmaceutical company’s stock worth $408,000 after acquiring an additional 65,833 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Proteon Therapeutics by 29.8% in the 2nd quarter. Renaissance Technologies LLC now owns 306,481 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 70,381 shares during the last quarter. Institutional investors own 54.37% of the company’s stock.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.

Recommended Story: Why Net Income is Important to Investors

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.